An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and I in a 4 week on, 2 week off schedule in patients with advanced solid tumors.

被引：0
|
作者：
Eskens, F. A.
Planting, A.
Van Doorn, L.
Isoe, T.
Hayashi, K.
Hussain, S.
Ekman, L.
Burger, H.
Verweij, J.
机构：
[1] Erasmus MC, Rotterdam, Netherlands
[2] Kirin Co Ltd, Tokyo, Japan
[3] Quintiles, Uppsala, Sweden
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：87S / 87S
页数：1
相关论文
共 50 条
  • [31] Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors
    Okamoto, Isamu
    Arao, Tokuzo
    Miyazaki, Masaki
    Satoh, Taroh
    Okamoto, Kunio
    Tsunoda, Takuya
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    CANCER SCIENCE, 2012, 103 (12): : 2135 - 2138
  • [32] Phase 1 study with BIBW 2992, an irreversible dual tyrosine kinase inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) in a 2 week on 2 week off schedule.
    Mom, C. H.
    Eskens, F. A.
    Gietema, J. A.
    Nooter, K.
    De Jonge, M. J.
    Amelsberg, A.
    Huisman, H.
    Stopfer, P.
    De Vries, E. G.
    Verweij, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 127S - 127S
  • [33] Phase I, open-label, dose-escalation trial investigating the safety and efficacy of oncolytic virus BI 1821736 in patients with advanced solid tumors.
    Tolcher, Anthony W.
    Victoria, Ivan
    Germann, Nathalie
    Luecke, Stephan
    Bailey, Mark
    Kordes, Maximilian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Phase I dose escalation of ASKC202, a novel cMET tyrosine kinase inhibitor, in patients with advanced solid tumors
    Song, Tingting
    Zhou, Caicun
    Li, Wei
    Li, Xingya
    Wu, Lin
    Zeng, Shan
    Miao, Liyun
    Liu, Baogang
    Wei, Xuyu
    Chen, Jing
    Han, Luwei
    CANCER RESEARCH, 2024, 84 (07)
  • [35] A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours.
    Agus, D. B.
    Terlizzi, E.
    Stopfer, P.
    Amelsberg, A.
    Gordon, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 97S - 97S
  • [36] Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
    Desai, Jayesh
    Gan, Hui
    Barrow, Catherine
    Jameson, Michael
    Atkinson, Victoria
    Haydon, Andrew
    Millward, Michael
    Begbie, Stephen
    Brown, Michael
    Markman, Ben
    Patterson, William
    Hill, Andrew
    Horvath, Lisa
    Nagrial, Adnan
    Richardson, Gary
    Jackson, Christopher
    Friedlander, Michael
    Parente, Phillip
    Tran, Ben
    Wang, Lai
    Chen, Yunxin
    Tang, Zhiyu
    Huang, Wendy
    Wu, John
    Zeng, Dewan
    Luo, Lusong
    Solomon, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (19) : 2140 - +
  • [37] A phase I single dose escalation study of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumors.
    Mross, K
    Steinbild, S
    Frost, A
    Hedborn, S
    Rentschler, J
    Kaiser, R
    Trommeshauser, D
    Stehle, G
    Munzert, G
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9032S - 9032S
  • [38] A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.
    Bauer, Todd Michael
    Adkins, Douglas
    Schwartz, Gary K.
    Werner, Theresa Louise
    Alva, Ajjai Shivaram
    Hong, David S.
    Carvajal, Richard D.
    Saleh, Mansoor N.
    Bazhenova, Lyudmila
    Goel, Sanjay
    Eaton, Keith D.
    Siegel, Robert D.
    Wang, Ding
    Lauer, Richard C.
    Neuteboom, Saskia T. C.
    Faltaos, Demiana
    Chen, Isan
    Christensen, James
    Chao, Richard C.
    Heist, Rebecca Suk
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] A phase I study of a TGF-β receptor I kinase inhibitor YL-13027 in patients with advanced solid tumors.
    Li, Jin
    Liu, Tianshu
    Bao, Hanying
    Xu, Zusheng
    Shu, Yang
    Zheng, Binghua
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors.
    Gort, Eelke
    Johnson, Melissa Lynne
    Hwang, Jimmy J.
    Pant, Shubham
    Dunzinger, Ulrich
    Riemann, Kathrin
    Kitzing, Thomas
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345